TABLE VI.

Outcomes of engrafted survivors

Outcome	Patients (n = 48)
Alive and well with phenotype reversal	41 (85)
Full donor chimerism (>95%)*	33 (69)
Mixed CD3+ donor chimerism only (<95%)†	3 (6)
Mixed donor chimerism in both compartments (<95%)‡	3 (6)
Other§	2 (6)
Alive with phenotype reversal but significant ongoing complications||	4 (8)
Other	3 (6)
Partial phenotype reversal, mixed donor chimerism¶	2 (4)
Too early to evaluate phenotype reversal (<100 days post-HCT)	1 (2)

Values are n (%).

^*Whole blood or myeloid donor chimerism >95%; CD3⁺ chimerism, if available (n = 14), was >95%.

^†Whole blood or myeloid donor chimerism >95%; CD3⁺ chimerism <95% (9.2%, 40%, 93%).

^‡Whole blood or myeloid donor chimerism <95% (range, 52%−82%) and CD3⁺ himerism <95% (range, 67.5%−84%).

^§Whole blood donor chimerism <95% (n = 1, 94%) and full CD3⁺ donor chimerism but mixed myeloid and whole blood donor chimerism (n = 1, 96%, 86%, 90%, respectively).

^||Ongoing complications include GVHD (n = 2) and chronic kidney disease (n = 2). All have 100% donor chimerism.

^¶One patient has resolution of recurrent respiratory infections and enteropathy with negative EBV, CMV, and adenovirus in blood, but recent ocular HSV and VZV despite prophylaxis 2 years post-HCT; last donor chimerism: 35% whole blood, 26% myeloid, 34% CD3⁺, 17% CD19⁺. The other patient has improvement of disseminated Mycoplasma orale infection but continued immune thrombocytopenia and hypogammaglobulinemia 2.8 years post-HCT; last donor chimerism: 85% myeloid, 58% CD3⁺, 99% CD19⁺, 82% natural killer.